Page last updated: 2024-08-25

rosiglitazone and Dermatitis, Atopic

rosiglitazone has been researched along with Dermatitis, Atopic in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fujita, H; Jee, Y; Jung, K; Karasawa, K; Matsuda, A; Matsuda, H; Ohmori, K; Oida, K; Okamoto, N; Shin, T; Tanaka, A1
Behshad, R; Cooper, KD; Korman, NJ1

Other Studies

2 other study(ies) available for rosiglitazone and Dermatitis, Atopic

ArticleYear
Peroxisome proliferator-activated receptor γ-mediated suppression of dendritic cell function prevents the onset of atopic dermatitis in NC/Tnd mice.
    The Journal of allergy and clinical immunology, 2011, Volume: 127, Issue:2

    Topics: Animals; Cell Movement; Cytokines; Dendritic Cells; Dermatitis, Atopic; Matrix Metalloproteinase 9; Mice; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thymic Stromal Lymphopoietin

2011
A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis.
    Archives of dermatology, 2008, Volume: 144, Issue:1

    Topics: Administration, Oral; Adolescent; Adult; Aged; Allergens; Dermatitis, Atopic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Patch Tests; Patient Satisfaction; PPAR gamma; Retrospective Studies; Risk Factors; Rosiglitazone; Sampling Studies; Severity of Illness Index; Thiazolidinediones; Treatment Outcome

2008